Takeda’s agreement this week to acquire Shire plc for $62 billion promises to reshape, literally and figuratively, the biotech landscape in Kendall Square, where both companies have a sizable presence.
For one iconic property in particular, Tuesday’s deal has major implications: the Genzyme Center, which Shire (Nasdaq: SHPG) had been set to occupy starting next year.
The 350,000-square-foot building at 500 Kendall St. is the current headquarters of rare disease drugmaker Sanofi Genzyme. The company announced a few years ago that it planned to move to a new headquarters at nearby 50 Binney St. this year. A spokesperson for Sanofi Genzyme said Thursday that the moving process is now underway and will be completed this month.
Shire signed a lease for the building in late 2016, and had been planning to move in early next year. But following Tuesday’s buyout announcement, both Shire and Takeda have declined to say whether that is still the plan.
No comments:
Post a Comment